Abcl stock forecast.

https://www.abcellera.com. AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners.Planning a trip can be an exciting but challenging task. From booking accommodations to creating an itinerary, there are countless details to consider. One crucial aspect that should never be overlooked is checking the 7-day weather forecas...Nov 13. 12.44%. $57.49. Check if ABC Stock has a Buy or Sell Evaluation. ABC Stock Price (NYSE), Forecast, Predictions, Stock Analysis and AmerisourceBergen Corp (Holding Co) News.VIE : 53.01 (unch) AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript Motley Fool - Fri Aug 4, 12:00AM CDT. ABCL earnings call for the period ending June 30, 2023. ABCL : 4.18 (-5.00%) AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript Motley Fool - Thu May 4, 11:30PM CDT.

19 sept 2023 ... ... (ABCL) Stock's Price and Volume. The market has been down on AbCellera Biologics Inc (ABCL) stock recently. ABCL gets a Bearish score from ...This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 238.60% Increase from the current price of $4.43.

Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. AbCellera Biologics stock news, updates & related news. Find out why AbCellera Biologics's (ABCL) news sentiment is 14.35% more negative in relation to stocks in the Healthcare sector.

May 26, 2023 · ABCL Stock Performance: A Look at May 26, 2023. On May 26, 2023, Abcellera Biologics Inc (ABCL) saw a significant increase in its stock price, with shares trading at $28.00, up 306.39% from the previous day’s closing price. This surge in price can be attributed to the positive outlook of the 9 analysts who offer 12-month price forecasts for ABCL. What are the most recommended stocks by analysts? Robyn Karnauskas is a 4.27-star Wall Street Analyst at Truist Financial. Robyn Karnauskas's focuses on the Healthcare sector and covers 71 stocks with a 48.66% success rate.AbCellera Biologics Inc. Stock Forecast NASDAQ Stock Exchange > Healthcare > Biotechnology Open Broker Account $4.43 +0 (+0%) At Close: Nov 24, …Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -618.82% from its current level, while the stock would need to crash -111.42% from its current level to reach the projected low.Stock Price Forecast. The 8 analysts offering 12-month price forecasts for Abcellera Biologics Inc have a median target of 20.50, with a high estimate of 34.00 and a low estimate of 10.00. The median estimate represents a +323.99% increase from the …

ABCL's current lowest rank is in the Momentum metric (where it is better than 4.01% of US stocks). ABCL Stock Summary. The price/operating cash flow metric for ABCELLERA BIOLOGICS INC is higher than 98.57% of stocks in our set with a positive cash flow. ABCL's price/sales ratio is 23.26; that's higher than the P/S ratio of 95.29% of US stocks.

Recursion Pharmaceuticals Inc. 6.87. -0.18. -2.55%. Get Abcellera Biologics Inc (ABCL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Nov 29, 2023 · According to 40 analysts, the average rating for MSFT stock is "Strong Buy." The 12-month stock price forecast is $392.0, which is an increase of 3.51% from the latest price. Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating. ADMA Stock 12 Months Forecast. $6.00. (51.90% Upside) Based on 2 Wall Street analysts offering 12 month price targets for ADMA Biologics in the last 3 months. The average price target is $6.00 with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 51.90% change from the last price of $3.95.James O'Neil/DigitalVision via Getty Images. AbCellera Biologics ( NASDAQ: ABCL) to date has been quite a lousy investment. From the IPO high of $58.90, all the way down to the current price of ...NASDAQ Health Care/Life Sciences Compare to Open 4.41 Prior Close 4.34 (11/21/23) 1 Day ABCL 2.07% DJIA 0.53% S&P Mid Cap 400 0.58% Health Care/Life Sciences 0.45% Overview Per-Share Earnings,...

Based on 3 Wall Street analysts offering 12 month price targets for Workhorse Group in the last 3 months. The average price target is $2.83 with a high forecast of $4.00 and a low forecast of $1.50. The average price target represents a 626.01% change from the last price of $0.39. Highest Price Target $4.00. Average Price Target $2.83.The average stock forecast for Abcellera Biologics Inc (ABCL) is 22.44 USD. This price target corresponds to an upside of 364.60%. The range of stock forecasts for ABCL is …AbCellera Biologics Inc. research and ratings by Barron's. View ABCL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.AmerisourceBergen stock forecast report. View ABC price target, analyst ratings, upgrades & downgrades predictions, and buy or a sell data.Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $22.33, which predicts an increase of …

Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -618.82% from its current level, while the stock would need to crash -111.42% from its current level to reach the projected low.

Wall Street analysts forecast ABCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABCL is 24.35 USD with a low forecast of 12.12 USD and a high forecast of 35.7 USD. ABCL Lowest Forecast Wall Street Target. 12.12 ...Find the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing.Analyst Forecast. According to 7 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price forecast is $22.33, which is an …Vortex Energy Corp () Stock Market info Recommendations: Buy or sell Vertex Pharmaceuticals stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Vertex Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Vertex Pharmaceuticals's VRTX shares and …Now, shares are making a pullback to their 21-day line, creating a high handle for that cup base, and could offer investors a new entry. ABCL stock slipped 1.5% to close at 13.36 on the stock ...Adbri (ASX:ABC) pays an annual dividend of A$0.12 per share and currently has a dividend yield of 5.74%. ABC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 75.00%. This payout ratio is at a healthy, sustainable level, below 75%.Find the latest Standard Lithium Ltd. (SLI) stock quote, history, news and other vital information to help you with your stock trading and investing.

10 equities research analysts have issued twelve-month target prices for AbCellera Biologics' stock. Their ABCL share price …

Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Abcellera Biologics Inc (NASDAQ:ABCL) 4.76 Delayed Data As of 3:59pm ET +0.035 / +0.74% Today’s Change 3.87 Today ||| 52-Week Range 14.00 -52.96% Year-to-Date Quote Profile News Charts...AbCellera Biologics Inc. research and ratings by Barron's. View ABCL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.Analyst Forecast. According to 41 analysts, the average rating for NVDA stock is "Strong Buy." The 12-month stock price forecast is $609.89, which is an increase of 30.42% from the latest price.A high-level overview of AbCellera Biologics Inc. (ABCL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. According to 40 analysts, the average rating for MSFT stock is "Strong Buy." The 12-month stock price forecast is $392.0, which is an increase of 3.51% from the latest price.A high-level overview of AbCellera Biologics Inc. (ABCL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 19 jul 2023 ... AbCellera Biologics presents a complex yet intriguing investment case. Click here to see why ABCL stock is a Hold.What are the most recommended stocks by analysts? Robyn Karnauskas is a 4.27-star Wall Street Analyst at Truist Financial. Robyn Karnauskas's focuses on the Healthcare sector and covers 71 stocks with a 48.66% success rate.AbCellera Biologics Inc. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: ABCL | NasdaqFind the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing.Get the latest information on AbCellera Biologics Inc. (ABCL), a biotechnology company that discovers antibodies from natural immune responses. See its stock price, earnings, revenue, financial statements, analyst forecasts, news and more.

ABCL stock recorded 16/30 (53%) green days with 5.07% price volatility over the last 30 days. Based on our AbCellera Biologics stock forecast, it's now a bad time to buy ABCL stock because it's trading 6.53% above our forecast. Disclaimer: This is not investment advice. The information provided is for general information purposes only.Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. May 26, 2023 · ABCL Stock Performance: A Look at May 26, 2023. On May 26, 2023, Abcellera Biologics Inc (ABCL) saw a significant increase in its stock price, with shares trading at $28.00, up 306.39% from the previous day’s closing price. This surge in price can be attributed to the positive outlook of the 9 analysts who offer 12-month price forecasts for ABCL. AbCellera Biologics ( ABCL) started trading on the Nasdaq on December 11 last year. The issue price was $20, above the originally stated $14-17 range but based on the first day’s trading, still ...Instagram:https://instagram. metlife dental dppohow to get a mortgage loan without tax returnslivevox stockbest option traders The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...ABCL Stock Forecast - Is ABCL a buy or sell? Find out now with a free analysis on AbCellera Biologics. Should I buy or sell ABCL? ABCL Stock Analysis - [Full Report] ABCL Chart by TradingView. Antibodies Stocks Antibody Stocks Biologics Stocks Database Stocks Drug Stocks Immune Stocks Natural Stocks dpst holdingsis pypl a good stock to buy Abcellera Biologics Inc (NASDAQ:ABCL) 4.76 Delayed Data As of 3:59pm ET +0.035 / +0.74% Today’s Change 3.87 Today ||| 52-Week Range 14.00 -52.96% Year-to-Date Quote Profile News Charts...About the AbCellera Biologics Inc stock forecast. As of 2023 November 28, Tuesday current price of ABCL stock is 4.530$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception). cobalt miners stocks View AbCellera Biologics Inc ABCL investment & stock information. Get the latest AbCellera Biologics Inc ABCL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing.